These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8866946)

  • 1. Central nervous system characterization of the new cholecystokininB antagonist LY288513.
    Helton DR; Berger JE; Czachura JF; Rasmussen K; Kallman MJ
    Pharmacol Biochem Behav; 1996 Mar; 53(3):493-502. PubMed ID: 8866946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats.
    Izumi T; Inoue T; Tsuchiya K; Hashimoto S; Ohmori T; Koyama T
    Eur J Pharmacol; 1996 Apr; 300(1-2):25-31. PubMed ID: 8741161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.
    Rasmussen K; Czachura JF; Stockton ME; Howbert JJ
    J Pharmacol Exp Ther; 1993 Jan; 264(1):480-8. PubMed ID: 8423546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle.
    Rasmussen K; Czachura JF; Kallman MJ; Helton DR
    Neuroreport; 1996 Apr; 7(5):1050-2. PubMed ID: 8804049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety].
    Izumi T
    Hokkaido Igaku Zasshi; 1998 Sep; 73(5):463-73. PubMed ID: 9846276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition.
    Rasmussen K; Gates MR; Burger JE; Czachura JF
    Neurosci Lett; 1997 Jan; 222(1):61-4. PubMed ID: 9121724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response.
    Rasmussen K; Helton DR; Berger JE; Scearce E
    Ann N Y Acad Sci; 1994 Mar; 713():374-6. PubMed ID: 8185192
    [No Abstract]   [Full Text] [Related]  

  • 9. The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.
    Rasmussen K; Helton DR; Berger JE; Scearce E
    Neuroreport; 1993 Nov; 5(2):154-6. PubMed ID: 8111002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
    Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
    Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of an O-glucuronide metabolite of the CCK-B antagonist LY288513 and its plasma levels in mouse, rat, and dog.
    Woodland JM; Ehlhardt WJ
    Drug Metab Dispos; 1995 Sep; 23(9):910-5. PubMed ID: 8565780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat.
    Luo B; Cheu JW; Siegel A
    Brain Res; 1998 Jun; 796(1-2):27-37. PubMed ID: 9689451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGS 20625, a novel pyrazolopyridine anxiolytic.
    Williams M; Bennett DA; Loo PS; Braunwalder AF; Amrick CL; Wilson DE; Thompson TN; Schmutz M; Yokoyoma N; Wasley JW
    J Pharmacol Exp Ther; 1989 Jan; 248(1):89-96. PubMed ID: 2563294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
    Revel L; Mennuni L; Garofalo P; Makovec F
    Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a cholecystokinin agonist on masseter muscle activity in the cat.
    Sitthisomwong P; Weiner S; Levin L; Reisman S; Siegel A
    J Dent Res; 2000 Oct; 79(10):1823-8. PubMed ID: 11078001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice.
    Kuribara H; Stavinoha WB; Maruyama Y
    J Pharm Pharmacol; 1998 Jul; 50(7):819-26. PubMed ID: 9720634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
    Kuribara H; Weintraub ST; Yoshihama T; Maruyama Y
    J Nat Prod; 2003 Oct; 66(10):1333-7. PubMed ID: 14575433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CGS 9896: agonist-antagonist benzodiazepine receptor activity revealed by anxiolytic, anticonvulsant and muscle relaxation assessment in rodents.
    Bernard PS; Bennett DA; Pastor G; Yokoyama N; Liebman JM
    J Pharmacol Exp Ther; 1985 Oct; 235(1):98-105. PubMed ID: 2995650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
    Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
    J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.